TW200612969A - 3-β-d-ribofuranosylthiazolo[4,5-d]pyrimidine nucleosides and uses thereof - Google Patents

3-β-d-ribofuranosylthiazolo[4,5-d]pyrimidine nucleosides and uses thereof

Info

Publication number
TW200612969A
TW200612969A TW094118512A TW94118512A TW200612969A TW 200612969 A TW200612969 A TW 200612969A TW 094118512 A TW094118512 A TW 094118512A TW 94118512 A TW94118512 A TW 94118512A TW 200612969 A TW200612969 A TW 200612969A
Authority
TW
Taiwan
Prior art keywords
ribofuranosylthiazolo
pyrimidine nucleosides
compounds
directed
therapeutic
Prior art date
Application number
TW094118512A
Other languages
English (en)
Inventor
Devron R Averett
Stephen E Webber
Joseph R Lennox
Erik J Rueden
David Louis Clark
Alan X Xiang
Original Assignee
Anadys Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34959084&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=TW200612969(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Anadys Pharmaceuticals Inc filed Critical Anadys Pharmaceuticals Inc
Publication of TW200612969A publication Critical patent/TW200612969A/zh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/24—Heterocyclic radicals containing oxygen or sulfur as ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • Virology (AREA)
  • Biotechnology (AREA)
  • Communicable Diseases (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Hematology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
TW094118512A 2004-06-07 2005-06-06 3-β-d-ribofuranosylthiazolo[4,5-d]pyrimidine nucleosides and uses thereof TW200612969A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/US2004/018011 WO2005121162A1 (en) 2004-06-07 2004-06-07 3-β-D-RIBOFURANOSYLTHIAZOLO[4,5-d]PYRIDIMINE NUCLEOSIDES AND USES THEREOF

Publications (1)

Publication Number Publication Date
TW200612969A true TW200612969A (en) 2006-05-01

Family

ID=34959084

Family Applications (1)

Application Number Title Priority Date Filing Date
TW094118512A TW200612969A (en) 2004-06-07 2005-06-06 3-β-d-ribofuranosylthiazolo[4,5-d]pyrimidine nucleosides and uses thereof

Country Status (21)

Country Link
US (1) US20080070852A1 (zh)
EP (1) EP1758916B1 (zh)
JP (1) JP4856638B2 (zh)
CN (1) CN1964985A (zh)
AR (1) AR049203A1 (zh)
AU (1) AU2004320625B2 (zh)
BR (1) BRPI0418887A (zh)
CA (1) CA2566541C (zh)
ES (1) ES2399891T3 (zh)
IL (1) IL179529A0 (zh)
IS (1) IS8575A (zh)
MX (1) MXPA06014182A (zh)
NO (1) NO20070061L (zh)
PA (1) PA8635901A1 (zh)
PE (1) PE20060455A1 (zh)
RU (1) RU2006146204A (zh)
SV (1) SV2006002135A (zh)
TN (1) TNSN06403A1 (zh)
TW (1) TW200612969A (zh)
UY (1) UY28943A1 (zh)
WO (1) WO2005121162A1 (zh)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI407956B (zh) * 2004-12-17 2013-09-11 Anadys Pharmaceuticals Inc ３，５-二取代和３，５，７-三取代-３Ｈ-唑并及３Ｈ-噻唑并〔４，５-ｄ〕嘧啶-２-酮化合物及其前藥

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0009486D0 (en) 2000-04-17 2000-06-07 Univ Cardiff Chemical compounds
EP2007789B1 (en) 2006-04-11 2015-05-20 Novartis AG Spirocyclic HCV/HIV inhibitors and their uses
GB0609178D0 (en) * 2006-05-09 2006-06-21 Univ Cardiff Novel compounds
AR061024A1 (es) * 2006-05-22 2008-07-30 Novartis Ag Maleato de 5-amino-3- (2'3'-di-o-acetil-beta-d-ribofuranosil)-3h-tiazolo[4,5-d] pirimidin-2-ona.
BRPI0717741A2 (pt) * 2006-10-17 2014-04-08 Anadys Pharmaceuticals Inc Compostos e respectivos método de preparação, método de redução de composto de sulfonil substituído, composição farmacêutica método de tratamento ou prevenção de doença
PL2014771T3 (pl) * 2007-06-25 2015-05-29 Anadys Pharmaceuticals Inc Ciągły proces hydrolizy enzymatycznej
EP2019113A1 (en) * 2007-07-26 2009-01-28 Anadys Pharmaceuticals, Inc. New Crystalline Salts of 5-Amino-3-(2',3'-di-O-acetyl-beta-D-ribofuranosyl)-3H-thiazolo[4,5-d]pyrimidin-2-one
US8512690B2 (en) 2009-04-10 2013-08-20 Novartis Ag Derivatised proline containing peptide compounds as protease inhibitors
US20110182850A1 (en) 2009-04-10 2011-07-28 Trixi Brandl Organic compounds and their uses
KR101848099B1 (ko) * 2009-09-21 2018-04-11 길리애드 사이언시즈, 인코포레이티드 1'-치환된 카바-뉴클레오사이드 유사체의 제조를 위한 방법 및 중간체
US9011833B2 (en) 2010-10-08 2015-04-21 Novartis Ag Vitamin E formulations of sulfamide NS3 inhibitors
CN102153548B (zh) * 2011-02-24 2012-11-28 河北大学 一种含有噻唑（嗪）烷酮环的类核苷衍生物及其制备方法和其在药物制剂中的应用
WO2023196458A1 (en) * 2022-04-06 2023-10-12 VenatoRx Pharmaceuticals, Inc. Orally-bioavailable nucleoside analogs
CN116589606B (zh) * 2022-12-01 2024-05-28 中国药科大学 一种丁酰化酵母葡聚糖及其制备方法、应用

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4880784A (en) * 1987-12-21 1989-11-14 Brigham Young University Antiviral methods utilizing ribofuranosylthiazolo[4,5-d]pyrimdine derivatives
US5041426A (en) * 1987-12-21 1991-08-20 Brigham Young University Immune system enhancing 3-β-d-ribofuranosylthiazolo[4,5-d]pyridimine nucleosides and nucleotides
UA79764C2 (en) 2001-11-27 2007-07-25 Anadys Pharmaceuticals Inc 3-?-D-RIBOFURANOSYLTHIAZOLO[4,5-d]PYRIDIMINE NUCLEOSIDES AND USES THEREOF

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI407956B (zh) * 2004-12-17 2013-09-11 Anadys Pharmaceuticals Inc ３，５-二取代和３，５，７-三取代-３Ｈ-唑并及３Ｈ-噻唑并〔４，５-ｄ〕嘧啶-２-酮化合物及其前藥

Also Published As

Publication number Publication date
JP2008501792A (ja) 2008-01-24
AU2004320625B2 (en) 2009-08-27
AR049203A1 (es) 2006-07-05
EP1758916B1 (en) 2012-11-21
WO2005121162A1 (en) 2005-12-22
AU2004320625A1 (en) 2005-12-22
EP1758916A1 (en) 2007-03-07
RU2006146204A (ru) 2008-07-20
CA2566541A1 (en) 2005-12-22
IS8575A (is) 2006-12-05
SV2006002135A (es) 2006-05-08
MXPA06014182A (es) 2007-06-25
US20080070852A1 (en) 2008-03-20
UY28943A1 (es) 2006-01-31
NO20070061L (no) 2007-03-05
PE20060455A1 (es) 2006-06-19
CA2566541C (en) 2012-10-09
PA8635901A1 (es) 2006-07-03
CN1964985A (zh) 2007-05-16
IL179529A0 (en) 2007-05-15
TNSN06403A1 (en) 2008-02-22
ES2399891T3 (es) 2013-04-04
BRPI0418887A (pt) 2007-10-30
JP4856638B2 (ja) 2012-01-18

Similar Documents

Publication Publication Date Title
TW200612969A (en) 3-β-d-ribofuranosylthiazolo[4,5-d]pyrimidine nucleosides and uses thereof
YU45204A (sh) 3-BETA-D-RIBOFURANOZILTIAZOLO/4,5-d/ PIRIMIDINSKI NUKLEOZIDII NJIHOVA UPOTREBA
TNSN07208A1 (en) 3,5-DISUBTITUTED AND 3,5,7-TRISUBSTITUTED-3H-OXAZOLO AND 3H-THIAZOLO [4,5-d] PYRIMIDIN-2-ONE COMPOUNDS AND PRODRUGS THEREOF
TW200608979A (en) Pyrrolotriazine derivatives useful for treating hyper-proliferative disorders and diseases associated with angiogenesis
TW200724543A (en) Heterocyclic compounds and their uses as therapeutic agents
TW200716546A (en) Oxindole compounds and their uses as therapeutic agents
TW200800976A (en) New compounds for the treatment of neurological, psychiatric or pain disorders
WO2003096990A3 (en) Protein cages for the delivery of medical imaging and therapy
GB0222495D0 (en) Compounds
TW200611695A (en) Pyrrolopyridine derivatives
WO2004062625A3 (en) Macrocyclic beta-secretase inhibitors for treatment of alzheimer's disease
WO2007100366A3 (en) Quinolone m1 receptor positive allosteric modulators
UA83194C2 (ru) Производные пиримидина и их применение как модуляторов св2
EA200601212A1 (ru) Ингибиторы фосфодиэстеразы, получение и их терапевтическое применение
WO2005018545A3 (en) Macrocyclic beta-secretase inhibitors for the treatment of alzheimer's disease
MXPA05008438A (es) Heterociclil-3-sulfonilindazoles como ligandos de 5-hidroxitriptamina-6.
YU75603A (sh) Dihidropirimidinska jedinjenja koja su supstituisana na cijano grupi i njihova upotreba u lečenju oboljenja
WO2002079149A3 (en) Novel cyano-substituted dihydropyrimidine compounds and their use to treat diseases
AU2003260436A1 (en) Pyrimidine compounds
ATE451350T1 (de) Arylalkylsulfonamide als therapeutische mittel zur behandlung von knochenleiden
TW200603791A (en) Compounds and compositions as cathepsin S inhibitors
UA91697C2 (en) 3, 5-DISUBSTITUTED AND 3,5,7-TRISUBSTITUTED-3H-OXAZOLO AND 3H-THIAZOLO [4,5-d]PYRIMIDIN-2-ONE COMPOUNDS AND PRODRUGS THEREOF
WO2006110447A3 (en) Pyrimidine derivatives and their use in the treatment of cancer
DOP2005000261A (es) Compuestos de 3h-oxazolo y 3h-tiazolo [4,5-d] pirrimidin-2-ona 3,5-disustituida y 3,5,7-trisustituida y profarmacos de los mismo
UA87851C2 (ru) Производные пирролотриазина, применимые для лечения гиперпролиферативных нарушений и заболеваний, связанных с ангиогенезом